Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Enterprise Value (2016 - 2025)

UroGen Pharma's Enterprise Value history spans 10 years, with the latest figure at -$112.1 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 35.23% year-over-year to -$112.1 million; the TTM value through Dec 2025 reached -$112.1 million, up 35.23%, while the annual FY2025 figure was -$112.1 million, 35.23% up from the prior year.
  • Enterprise Value reached -$112.1 million in Q4 2025 per URGN's latest filing, up from -$127.0 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$811000.0 in Q2 2022 to a low of -$249.6 million in Q3 2024.
  • Average Enterprise Value over 5 years is -$113.5 million, with a median of -$109.2 million recorded in 2021.
  • Peak YoY movement for Enterprise Value: skyrocketed 98.74% in 2022, then plummeted 2482.37% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$45.6 million in 2021, then crashed by 119.29% to -$100.0 million in 2022, then crashed by 37.02% to -$137.0 million in 2023, then decreased by 26.35% to -$173.1 million in 2024, then skyrocketed by 35.23% to -$112.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Enterprise Value are -$112.1 million (Q4 2025), -$127.0 million (Q3 2025), and -$157.0 million (Q2 2025).